{
    "nctId": "NCT02088684",
    "briefTitle": "Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer",
    "officialTitle": "A Phase Ib/II Study of LEE011 in Combination With Fulvestrant and BYL719 or BKM120 in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Recurrent or Advanced Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 70,
    "primaryOutcomeMeasure": "Incidence of Dose limiting toxicities (DLTs) - Phase lb only",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal, Hormone receptor positive (HR+), HER2 negative breast cancer\n* Unlimited number of lines of endocrine therapy and up to two lines of cytotoxic chemotherapy in the metastatic setting (Phase Ib)\n* Unlimited number of lines of endocrine therapy and one line of cytotoxic chemotherapy in the metastatic setting (Phase II)\n\nExclusion Criteria:\n\n* HER2-overexpression in the patient's tumor tissue\n* Inadequate bone marrow function or evidence of end-organ damage\n* Severe or uncontrolled medical issues\n* Diabetes mellitus\n\nOther protocol-defined inclusion/exclusion criteria may apply",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}